IP Library Granted Patent US 9,284,279
Granted Patent B2
US 9,284,279 · App. 14/466,713 · Granted Mar 15, 2016

Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough

Inventors: Anthony P. Ford (Palo Alto, CA); Bruce G. McCarthy (San Francisco, CA)
Assignee: Afferent Pharmaceuticals, Inc.
C07D239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,284,279
App. No.
14/466,713
Granted
Mar 15, 2016
Kind
B2
Abstract

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are as defined herein.

Claims (28)

1. A method for treating chronic cough in a patient in need thereof, the method comprising administering to said patient an effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen or C 1 -C 6 alkyl optionally substituted with cycloalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, acylamino, mono-alkylamino, di-alkylamino, haloalkoxy, heteroalkyl, —COR wherein R is hydrogen, alkyl, phenyl or phenylalkyl, —(CR′R″) n —COOR wherein n is 0, 1, 2, 3, 4 or 5, R′ and R″ are independently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl, or —(CR′R″) n —CONR a R b wherein n is 0, 1, 2, 3, 4 or 5, R′ and R″ are independently hydrogen or alkyl, and R a and R b are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl; and

R 2 is alkyl, alkenyl, alkynyl, amino, aminosulfonyl, halo, amido, alkoxy, hydroxy, haloalkoxy, nitro, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkynylalkoxy, alkylsulfonyl, arylsulfonyl, carboxyalkyl, cyano or alkylcarbonyl.

2. The method of claim 1 , wherein the chronic cough is idiopathic or treatment resistant cough.

3. The method of claim h wherein the compound of Formula (I) is administered at about 600 mg twice daily.

4. The method of claim 1 , wherein the compound of Formula (I) is administered for about 2 weeks.

5. The method of claim 1 , wherein the compound of Formula (I) is administered at about 600 mg twice daily for about two weeks.

6. The method of claim 1 , wherein the chronic cough is refractory chronic cough.

7. The method of claim 1 , wherein the chronic cough is reduced by about 75%.

8. The method of claim 1 , wherein the chronic cough is daytime chronic cough.

9. The method of claim 1 , wherein R 1 is hydrogen or methyl.

10. The method of claim 1 , wherein R 2 is haloalkyl, aminosulfonyl, alkylsulfonyl, alkylcarbonyl or carboxyalkyl.

11. The method of claim 1 , wherein the compound is

12. A method for treating neuronal hypersensitivity underlying acute, sub-acute, or chronic cough in a patient in need thereof, the method comprising administering to said patient an effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen or C 1 -C 6 alkyl optionally substituted with cycloalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, acylamino, mono-alkylamino, di-alkylamino, haloalkoxy, heteroalkyl, —COR wherein R is hydrogen, alkyl, phenyl or phenylalkyl, —(CR′R″) n —COOR wherein n is 0, 1, 2, 3, 4 or 5, R′ and R″ are independently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl, —(CR′R″) n —CONR a R b wherein n is 0, 1, 2, 3, 4 or 5, R′ and R″ are independently hydrogen or alkyl, and R a and R b are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl; and

R 2 is alkyla alkenyl, alkynyl, amino, aminosulfonyl, halo, amido, haloalkyl, alkoxy, hydroxy, haloalkoxy, nitro, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkynylalkoxy, alkylsulfonyl, arylsulfonyl, carboxyalkyl, cyano or alkylcarbonyl.

13. The method of claim 12 , wherein the chronic cough is idiopathic or treatment resistant cough.

14. The method of claim 12 , wherein the compound of Formula (I) is administered at about 600 mg twice daily.

15. The method of claim 12 , wherein the compound of Formula (I) is administered for about 2 weeks.

16. The method of claim 12 , wherein the compound of Formula (I) is administered at about 600 mg twice daily for about two weeks.

17. The method of claim 12 , wherein the chronic cough is refractory chronic cough.

18. The method of claim 12 , wherein the chronic cough is reduced by about 75%.

19. The method of claim 12 , wherein the chronic cough is daytime chronic cough.

20. A method for treating chronic cough in a patient in need thereof, the method comprising administering to said patient an effective amount of a compound is selected from:

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 30, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 061877/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: FORD, ANTHONY P.; MCCARTHY, BRUCE G.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 033912/0455 →
Continuity (2)
Provisional Application 61869174 · Aug 23, 2013
Related Publication 20150057299A1 · Feb 26, 2015